We are already using omalizumab routinely for IgE depletion in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization, with accumulating but mainly case series-based clinical data to support this approach [145–147]. This evidence concerns the gene IGHE and asthma.